Literature DB >> 12750178

Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF delivery.

Ofer Yanay1, Simon C Barry, Louis J Katen, Margaret Brzezinski, Lisa Y Flint, Jeffrey Christensen, Denny Liggitt, David C Dale, William R A Osborne.   

Abstract

Cyclic neutropenia is a rare disease that occurs both in humans and gray collie dogs and is characterized by recurrent severe neutropenia leading to bacterial infections and shortened life expectancy. Daily injections of recombinant granulocyte colony-stimulating factor (rG-CSF) are effective in shortening the period of severe neutropenia and reducing infections. After demonstrating that rG-CSF induced elevated neutrophil production in an affected dog, cytokine administration was stopped and 109 infectious units (IUs) of a lentivirus pseudotyped with vesicular stomatitis virus G protein (VSV-G) encoding canine G-CSF cDNA was administered intramuscularly. Serial blood cell counts showed elevated neutrophil production for longer than 17 months. Although neutrophil counts continued to cycle, the range at nadirs was from 3710 to 5300 cells/microL, well above the nadirs before lentivirus administration. After the injection of lentivirus, mean neutrophil counts +/- SD were 12 460 +/- 4240 cells/microL, significantly increased over both pretreatment values of 3040 +/- 2540 cells/microL(P <.0001) and neutrophil counts during G-CSF administration of 10 290 +/- 4860 cells/microL(P <.007). The changes in blood counts from lentivirus injection were associated with absence of clinical signs of infection and fever. The gray collie continued to gain weight and was no longer housed in a pathogen-free environment. Genomic DNA from muscle at injection sites was positive for provirus, whereas gonad, lung, spleen, heart, liver, kidney, leukocytes, and noninjected muscle samples were all negative for provirus. Thus, intramuscular administration of lentivirus encoding G-CSF provided sustained therapeutic levels of neutrophils, suggesting this approach may be applied for long-term treatment of patients with cyclic and other neutropenias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750178     DOI: 10.1182/blood-2002-12-3722

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.

Authors:  Oumeya Adjali; Gilles Marodon; Marcos Steinberg; Cédric Mongellaz; Véronique Thomas-Vaslin; Chantal Jacquet; Naomi Taylor; David Klatzmann
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

2.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

3.  Repeated lentivirus-mediated granulocyte colony-stimulating factor administration to treat canine cyclic neutropenia.

Authors:  Ofer Yanay; David C Dale; William R A Osborne
Journal:  Hum Gene Ther       Date:  2012-09-12       Impact factor: 5.695

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.